Indications for Liver Transplantation

General Framework: Why Transplant?

Liver transplantation is indicated when (1) liver disease is expected to cause death or severe morbidity without transplant, (2) liver disease is not likely to recur or progress fatally after transplant, and (3) the patient has a reasonable chance of surviving the transplant surgery and achieving acceptable long-term outcomes. These three principles underpin every listing decision.

Major Indications

1. Decompensated Chronic Liver Disease

The most common indication. Decompensation is defined by the development of:

• Ascites (especially refractory ascites requiring repeated paracentesis)
• Spontaneous bacterial peritonitis
• Variceal hemorrhage
• Hepatic encephalopathy
• Hepatorenal syndrome

MELD 3.0 ≥15 is generally considered the threshold at which survival benefit from transplantation outweighs operative risk. Below MELD 15, the risk of surgery may exceed the risk of continued medical management.

Common underlying etiologies: alcohol-related liver disease, MASLD/MASH, chronic HBV, chronic HCV (now largely curable with DAAs — transplant indication declining), autoimmune hepatitis, PBC, PSC.

2. Acute Liver Failure (ALF)

ALF is defined as hepatic encephalopathy and coagulopathy (INR ≥1.5) within 26 weeks of onset of liver disease in a patient without prior chronic liver disease. It carries a mortality of >80% without transplantation.

Causes: Acetaminophen toxicity (most common in US — can recover with NAC if caught early), viral hepatitis (HAV, HBV), drug-induced liver injury, Wilson's disease, autoimmune hepatitis, Budd-Chiari, indeterminate.

King's College Criteria: Used to identify which ALF patients are unlikely to survive without transplant. Acetaminophen criteria: pH <7.30 OR (PT >100s AND creatinine >3.4 AND Grade III-IV HE). Non-acetaminophen criteria: PT >100s OR any 3 of [age <10 or >40, DILI or Wilson's, jaundice >7 days before HE, bilirubin >17.5, PT >50s].

ALF patients are listed as Status 1A — the highest priority in UNOS allocation, bypassing MELD-based scoring entirely.

3. Hepatocellular Carcinoma (HCC)

HCC arising in cirrhotic livers is a major indication for transplantation. Transplant offers the dual benefit of treating the cancer and the underlying cirrhosis.

Milan Criteria (standard): 1 lesion ≤5 cm OR 2–3 lesions each ≤3 cm, no vascular invasion, no extrahepatic spread. Patients within Milan criteria receive MELD exception points — an upward adjustment to their MELD score to compensate for the fact that HCC itself does not raise creatinine, bilirubin, or INR.

UCSF Criteria: Expanded criteria (1 lesion ≤6.5 cm OR 2–3 lesions ≤4.5 cm each and total tumor diameter ≤8 cm) adopted by some centers with comparable outcomes.

Bridging therapy (TACE, ablation) is often used to prevent tumor progression while awaiting transplant.

4. Cholestatic Liver Diseases

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) can progress to cirrhosis requiring transplantation. PSC also carries significant risk of cholangiocarcinoma — a contraindication to transplant in most cases.

5. Metabolic Liver Diseases

Wilson's disease (presenting as ALF — Status 1A), hereditary hemochromatosis (advanced cirrhosis), alpha-1 antitrypsin deficiency, and others may require transplantation.

6. Alcohol-Associated Liver Disease (ALD) — Candidacy Nuances

ALD with decompensated cirrhosis is a major transplant indication. A critical misconception persists in clinical practice: there is no universal fixed sobriety interval required for transplant listing. The traditional "6-month rule" has no prospective evidence base — it was derived from expert consensus and was historically used to allow potential liver recovery, not as a predictor of post-transplant alcohol use.

The current AASLD/AST framework emphasizes individualized assessment:

• Engagement in alcohol use disorder (AUD) treatment and counseling (AA, addiction medicine referral, naltrexone, acamprosate) demonstrates insight and commitment — this is more prognostically meaningful than duration of abstinence alone
• Social support, acknowledgment of alcohol use as the primary disease driver, and absence of other untreated substance use disorders are key factors
• Patients with more severe disease (higher MELD, life expectancy <90 days without transplant) may be listed on a shorter timeline when the risk of waitlist mortality outweighs the benefit of a prolonged observation period
• Continued monitoring post-transplant through follow-up labs, biomarker testing (PEth), and addiction support is standard of care

7. Severe Alcohol-Associated Hepatitis (AAH) as a Transplant Indication

Transplantation for severe alcohol-associated hepatitis (SAH) — defined as Maddrey Discriminant Function ≥32 or MELD ≥20 — is an emerging, center-specific indication performed at selected programs. It is not a universal standard.

Who is considered?

• Patients who have failed corticosteroid therapy (Lille score ≥0.45 at day 7) or who have contraindications to steroids (active infection, GI bleeding, renal failure)
• No prior history of decompensated liver disease (first presentation of severe liver disease)
• Strong psychosocial support and family commitment documented
• Acknowledgment of diagnosis and commitment to abstinence and AUD treatment post-transplant
• Absence of other active substance use disorders

Early US and European experience (Mathurin NEJM 2011; early LT for SAH) demonstrated 2-year survival of ~80%, with rates of return to alcohol use (~25%) comparable to or better than patients transplanted for ALD cirrhosis with documented abstinence. The selection process is highly stringent — the transplant team, social work, addiction psychiatry, and multidisciplinary selection committees all participate.

8. Non-HCC Oncologic Indications — OPTN Special Exception Pathways

Beyond HCC, the OPTN maintains formal special exception pathways for several malignant and non-malignant indications. These pathways require peer-reviewed regional review board approval on a case-by-case basis. Each has specific eligibility criteria and requires specialized center experience.

9. Polycystic Liver Disease (PLD)

Isolated polycystic liver disease (PCLD) and hepatic cysts in the context of autosomal dominant polycystic kidney disease (ADPKD) can cause massive hepatomegaly with significant morbidity. Liver function is often preserved despite enormous cyst burden — MELD may be low, but quality of life and nutritional status are severely impaired.

Indications for transplant consideration in PLD:

• Severe symptoms from mass effect: extrinsic compression of the GI tract (early satiety, nausea, vomiting, inability to maintain nutrition), respiratory compromise from diaphragm elevation
• Portal hypertension from compression of hepatic vascular structures by cysts
• Protein-calorie malnutrition refractory to nutritional support
• Renal failure requiring dialysis in ADPKD: combined liver-kidney transplant is the preferred option
• History of kidney transplant in ADPKD with progressive hepatic disease

Key Contraindications

Absolute: Active extrahepatic malignancy, active untreated infection outside the biliary tree, active alcohol or drug use (variable by program — typically require documented abstinence period), severe cardiopulmonary disease precluding surgery, anatomic precluding transplant, cholangiocarcinoma (most cases).

Relative: Age >70, severe obesity (BMI >40), prior complex abdominal surgery, multi-organ dysfunction — evaluated case by case.

The Evaluation Process

Transplant evaluation is multidisciplinary and typically involves:

• Hepatology: confirm indication, optimize medical management, calculate MELD
• Transplant surgery: assess operative candidacy and anatomy
• Cardiology: cardiac risk stratification (echo, stress test, right heart cath)
• Pulmonology: exclude hepatopulmonary syndrome, portopulmonary hypertension
• Nephrology: assess baseline renal function
• Psychiatry / social work: assess psychosocial support, substance use history, adherence capacity
• Financial counselor: insurance and compliance verification
• Infectious disease: vaccination review, latent TB screening